U.S. Markets closed

ArQule, Inc. (ARQL)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.20-0.06 (-4.76%)
At close: 4:00PM EDT
People also watch
ARRYCRISAVEOIMGNAMRI

ArQule, Inc.

One Wall Street
Burlington, MA 01803
United States
781-994-0300
http://www.arqule.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees34

Key Executives

NameTitlePayExercisedAge
Mr. Paolo PucciChief Exec. Officer and Director753.33k173.55k56
Mr. Peter S. Lawrence J.D.Pres, Chief Operating Officer, Gen. Counsel and Sec.607.43kN/A54
Mr. Robert J. WeiskopfChief Financial Officer and Treasurer406.42kN/A66
Dr. Brian Schwartz M.D.Chief Medical Officer and Sr. VP of Clinical & Regulatory Affairs585.74kN/A55
Dawn Schottlandt CFASr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The company’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of Bruton’s tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

Corporate Governance

ArQule, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.